{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-241951","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2025-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.368880+00:00","generated_at":"2026-05-17T03:24:53.259430+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Climb Bio reports long-term Phase 1b data for budoprutug; up to 3-year proteinuria control","bullets":["Abstract published for budoprutug (anti-CD19 mAb) showing durable proteinuria control up to 3 years in four PMN patients.","Three of four patients required no further immunosuppressive treatment after up to 4 doses.","No treatment-related adverse events grade 3 or higher observed in the Phase 1b trial (NCT04652570).","Data support continued development of budoprutug for B-cell mediated diseases.","Company remains focused on advancing its pipeline; risks include clinical and regulatory uncertainties."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-241951","json":"https://secwatch.observer/filing/0001193125-25-241951.json","markdown":"https://secwatch.observer/filing/0001193125-25-241951.md","text":"https://secwatch.observer/filing/0001193125-25-241951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525241951/0001193125-25-241951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312525241951/d34212d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:24:53.259430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}